Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

    NEXT STORY
    World Market for Medical Gloves 2020-2024: Insights & Forecasts with Potential Impact of COVID-19
    PREV STORY
    Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Immunovaccine to Present at 2018 BIO CEO & Investor Conference

    HALIFAX, Nova Scotia, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

    author_avatar
    NASDAQ Market News

    MacroGenics to Present at the Wedbush PacGrow Healthcare Conference

    ROCKVILLE, MD, Aug. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

    author_avatar
    NASDAQ Market News